Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo (Q39429719)

11 September 2017

Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo (English)

1 reference

non-small-cell lung carcinoma

11 September 2017

1 reference

Hang Zhu

1

1 reference

11 September 2017

Hua Cheng

2

1 reference

11 September 2017

Yuan Ren

3

1 reference

11 September 2017

Zhan Guo Liu

4

1 reference

11 September 2017

Yi Fang Zhang

5

1 reference

11 September 2017

Bing De Luo

6

1 reference

11 September 2017

9 December 2011

1 reference

Molecular Biology Reports

11 September 2017

1 reference

11 September 2017

39

1 reference

11 September 2017

4

1 reference

11 September 2017

4971-4979

1 reference

https://scigraph.springernature.com/pub.10.1007/s11033-011-1293-1

11 September 2017

0 references

cites work

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Lung cancer in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Current standards of care in small-cell and non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

New treatment approaches for lung cancer and impact on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Multi-targeted therapy of cancer by genistein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Mechanisms of cancer chemoprevention by soy isoflavone genistein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Using chemopreventive agents to enhance the efficacy of cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Genistein and beta-carotene enhance the growth-inhibitory effect of trichostatin A in A549 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Phytoestrogens and inhibition of angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

PI3K/Akt and apoptosis: size matters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Regulation of cell death protease caspase-9 by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Kaempferol induces cell death through ERK and Akt-dependent down-regulation of XIAP and survivin in human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Neonatal estrogenic exposure suppresses PTEN-related endometrial carcinogenesis in recombinant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Evidence that low-dose, long-term genistein treatment inhibits oestradiol-stimulated growth in MCF-7 cells by down-regulation of the PI3-kinase/Akt signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein) in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Epidermal Growth Factor Receptor Double Activating Mutations Involving Both Exons 19 and 21 Exist in Chinese Non-small Cell Lung Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-1293-1

Anticancer therapeutic potential of soy isoflavone, genistein.

21 January 2018

1 reference

12 December 2020

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

12 December 2020

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

1 reference

12 December 2020

Evidence for a role of EGF receptor in the progression of human lung carcinoma

1 reference

12 December 2020

10.1007/S11033-011-1293-1

Identifiers

DOI

1 reference

11 September 2017

1 reference